

Serum Fetuin-A Levels in Type 2 Diabetes Patients with Early Diabetic Nephropathy: It's Relation to Diabetes Control

^{1*}Ayman Ramadan, ¹Amira Shoukry, ¹Mabrouk I. Ismail and ²Maher Borai

¹Internal Medicine, ²Clinical Pathology Departments, Faculty of Medicine, Zagazig University, Zagazig, Egypt
aymedman@yahoo.co.uk

Abstract: Background and objective: Fetuin-A is a circulating calcium-regulatory glycoprotein that inhibits vascular calcification. In the present study, serum fetuin-A was studied as a novel risk factor for the development of diabetic nephropathy and the relation between its levels with the state of diabetes control. Patients and Methods: 50 patients with type 2 diabetes mellitus (T2DM) and early diabetic nephropathy, 25 patients of them have well controlled diabetes on treatment (the first group), the other 25 patients have uncontrolled diabetes (the second group), and another 25 healthy volunteers (control group) were enrolled in this cross sectional study. Serum fetuin-A, Fasting plasma glucose (FP glucose), glycosylated hemoglobin A1c, lipid profile (total cholesterol, HDL and triglycerides), Serum creatinine, Glomerular filtration rate (GFR), Albumin excretion in urine were measured. Results: There was a significant reduction in Serum fetuin-A levels in controlled diabetic patients (314 ± 66.8) and uncontrolled diabetic patients (252.4 ± 55.6) compared to control group (478.6 ± 74.4). A significant decrease was also detected in uncontrolled diabetic patients when compared to controlled diabetic patients ($P < 0.001$). A strong inverse correlation was found between serum fetuin-A and each of F P glucose, glycosylated hemoglobin (HbA1c), serum creatinine, and urinary albumin excretion ($r = -0.52, -0.55, -0.61, \text{ and } -0.56$ respectively; $P < 0.001$ for each). Whereas; GFR was significantly positively associated with serum fetuin-A levels ($r = 0.53, P < 0.001$). Conclusion: The results of this study demonstrate that diabetic nephropathy, especially with uncontrolled diabetes, is linked to low serum fetuin-A levels which represents a novel risk factor for the development of vascular complications. This factor could be responsible for the development and progression of accelerated nephropathy especially with uncontrolled diabetes.

[Ayman Ramadan, Amira Shoukry, Mabrouk Ibraheem Ismail, Maher Borai. **Serum Fetuin-A levels in type 2 diabetes patients with early diabetic nephropathy: Its relation to diabetes control.** Journal of American Science 2011;7(5):299-304]. (ISSN: 1545-1003). <http://www.americanscience.org>.

Keywords: Diabetic nephropathy; fetuin-A; Glycosylated hemoglobin A1c; diabetes mellitus; and control.

1. Introduction:

Various biomarkers have been studied for identification of type 2 diabetes patients at micro- and macrovascular risk. Most of these markers are inflammatory, metabolic or procoagulant molecules indicating an unfavorable metabolic and vascular status in patients with type 2 diabetes [1]. However, the different biomarkers show large variations in risk prediction depending on metabolic status and disease severity of the study groups [2,3]. Recently published data imply, that most novel biomarkers do not improve risk prediction when added to models based on conventional risk scores [4] Yet, associations of novel biomarkers such as fetuin-A with metabolic markers or complications do help to understand their role in the pathophysiology of vascular disease.

Fetuin-A, a circulating calcium-regulatory glycoprotein that inhibits vascular calcification, is predominantly synthesized in liver. It is secreted into the blood stream and deposited as a noncollagenous protein in mineralized bones and teeth. During fetal life, there is high serum concentration of fetuin-A. Its level declines following infection, acute or chronic inflammatory states and malignancy [5,6]. Low

serum fetuin-A levels have been reported in chronic renal disease and dialysis patients and is associated with inflammation and outcome [7,8]. Recent data have shown a relationship between vascular calcification and endothelial dysfunction in vascular disease [9]. Therefore, low serum fetuin-A level could be one of the contributing factors for the development of endothelial dysfunction in chronic renal disease patients.

So far, there is few data available for associations of fetuin-A with parameters of microvascular disease in diabetes. To clarify the relation between fetuin-A and microvascular complications in patients with type 2 diabetes and early diabetic nephropathy, we studied its associations with albuminuria and parameters of renal function. In addition, the state of diabetes control of these patients was assessed by quantification of the glycosylated hemoglobin A1c and its association with fetuin-A levels was assessed.

2. Methods

Study population and data collection

This study was carried out in Internal Medicine and Clinical Pathology departments, faculty of medicine, Zagazig University. This cross sectional study was conducted from January 2010 to January 2011.

This study included 50 patients with type 2 diabetes mellitus (T2DM) and early diabetic nephropathy who were recruited from the outpatient clinics of Endocrinology and Diabetes at Zagazig University Hospital and referred to the diabetes control for specialist treatment. The selection of patient groups was as follows:

25 patients were selected to have well controlled diabetes on treatment (First group): They were 13 males & 12 females, having a mean age of 53.76 ± 6.0 years, and a mean HbA1c of 6.2 ± 0.7 .

25 patients were selected to have uncontrolled diabetes on treatment (second group): They were 13 males & 12 females, having a mean age of 55 ± 6.2 years, and a mean HbA1c of 11 ± 2.1 .

Another age and sex matched 25 healthy volunteers were chosen as a control group.

Inclusion criteria: patients with T2DM who had to have a documented history of albuminuria in at least two separate urine samples (urinary albumin > 20 mg/L as suggested by current German and international guidelines for the diagnosis of diabetic nephropathy) [10].

Exclusion criteria: We excluded patients with malignant neoplasms, severe infectious disease, severe congestive heart failure, type 1 diabetes and other renal disease by urinary sediments and medical records (macroscopic hematuria, abnormal sediment, urinary tract infection and past history of glomerulonephritis or nephro-ureterolithiasis).

All patients were submitted to full clinical assessment including history taking and through clinical examination including blood pressure measurements (systolic and diastolic) and assessment of body mass index (BMI). In all individuals, 24-h urine samples were collected and the albumin excretion rate in 24 hours is estimated. The study complied with the Declaration of Helsinki, and all subjects gave informed consent to participate in this study.

Clinical chemistry

Blood was drawn in a fasting state under sterilized conditions and stored at -80°C until analysis. The following investigations were done:

Fasting plasma glucose (FPglucose) was measured by a glucose oxidase method. Triglyceride (TG), total cholesterol, and high density lipoprotein cholesterol (HDL) levels were quantified by using ADVIA 1650 auto analyzer (Siemens Medical Solutions Diagnostic, USA). Glycosylated

hemoglobin (Hb A1c) was estimated by ion exchange resin chromatography using Stanbio Glycohemoglobin.

Glomerular filtration rate is estimated from the Modification of Diet in Renal Disease (MDRD) formula [11] as follows: MDRD formula = $186 \times [\text{serum creatinine (mg/dl)}]^{-1.154} \times [\text{age}]^{0.203} \times [0.742 \text{ if patient is female}] \times [1.21 \text{ if patient is African-American}]$, which is used for statistical evaluation of renal function.

Albumin excretion rate (AER) was assessed and performed in 24-h urinary collections. For collection of the urine sample, a 3-l plastic container was used, and the volume of urine was measured to the nearest 50 ml. Albumin levels were determined by turbidimetry (Siemens Healthcare Diagnostics, Eschborn, Germany). AER was expressed as milligrams per 24 h.

Serum fetuin-A was measured in duplicates by an ELISA (Epitope Diagnostics, Inc., San Diego, USA) The intra- and interassay variations were 5.3 and 7.1%, respectively.

Statistical analyses

Statistical analyses of the results were performed using SPSS software version 15.0 (statistical package for social science, SPSS inc. Chicago, USA). Continuous variables were expressed as means \pm standard deviation (SD). Comparison between two sets of patients was performed by independent t test, but more than two sets of patients were compared by one-way ANOVA. The Kruskal-Wallis (KW) test was applied to compare the values of HbA1c, F P glucose and Albumin in urine (non normal distributed variables) among the three groups of the study. Pearson correlation coefficient r was used to describe the association between serum fetuin-A and the variables of interest. P values < 0.05 were considered statistically significant.

3. Results:

Clinical and laboratory characteristics of all patients with diabetes mellitus and healthy control subjects and comparison between all groups are given in Table 1.

There were no differences in age { $P=0.6$ }, sex { $P=0.94$ }, duration of diabetes { $P=0.97$ }, body mass index (BMI) { $P=0.2$ }, systolic blood pressure { $P=0.06$ }, diastolic blood pressure { $P=0.54$ }, and serum albumin { $P=0.75$ } among all groups of the study. There was no differences in the percentage of diabetic patients on treatment by ACE or insulin therapy between the two groups of diabetes mellitus { $P=0.77$ and 0.67 respectively}.

Table 1: Demographic, Clinical and laboratory characteristics of the studied groups.

Parameter	Control group n=25	Controlled diabetic group n=25	Uncontrolled diabetic group n=25	F /X ² / t	P
Age (y)	53.6 ± 6.1	53.76 ± 6.0	55 ± 6.2	0.4	0.6
Gender (M/F)	12(48%)/13(52%)	13(52%)/12(48%)	13(52%)/12(48%)	0.11	0.94
BMI (kg/m ²)	25.1 ± 4.1	26.8 ± 2.4	26.2 ± 3.2	1.6	0.2
Duration (y)		10.6± 4.9	10.56±4.9	0.02	0.97
Systolic B P (mmHg)	118.5±5.1	122.5±8.2	123.8±10.5	2.8	0.06
Diastolic B P(mmHg)	77.7±4.0	78.4±5.0	76.9±5.1	0.61	0.54
ACE therapy (n,%)		12 (48%)	13 (52%)	0.08	0.77
Insulin therapy (n,%)		14 (56%)	12 (48%)	0.32	0.67
HbA1c (%)					
X±SD	5.4 ± 0.5	6.2 ± 0.7 ⁺	11.0 ± 2.1 *	KW	<0.001**
Range	4.4 – 6.1	5.9 - 6.7	7.5 – 15.0	49.6	
Median	5.4	6.4	11		
F P glucose (mg/dl)					
X ± SD	82.3 ± 7.8	92.2± 12.82 ⁺	127.3 ± 20.2 *	KW	<0.001**
Range	70 – 97	70 – 120	89 – 170	47.69	
Median	83	94	125		
Serum creatinine (mg/dl)	0.55 ± 0.12*	0.9 ± 0.18	0.95 ± 0.19	41.1	<0.001**
GFR (ml/min/1.73m ²)	126.4±14.6*	103.1±14.6	95.5±17.7	26.1	<0.001**
Serum albumin (gm/dl)	4.5± 0.3	4.4±0.3	4.4±0.35	0.27	0.75
Triglycerides (mg/dl)	119.2± 23.3*	160.2± 43.7	157.2± 49.4	7.99	<0.001**
Total cholesterol (mg/dl)	160.2±23.3 *	194.5±42.3	205 ±47.1	9.5	<0.001**
HDL (mg/dl)	52.5±9.7 *	45.9±7.0	42.7±8.1	8.94	<0.001**
Albumin excretion (mg/24h)					
X ± SD	6.7± 3.1	188.4± 114 ⁺	243± 140.5 *	KW	<0.001**
Range	2 – 13	40 – 450	56 – 560	50.13	
Median	6	160	247		
Serum fetuin-A (mg/L)	478.6±74.4	314± 66.8 ⁺	252.4± 55.6*	78.3	<0.001**

**P is significant.

KW, The Kruskal-Wallis test.

* Significance is present between this group and the other two groups.

⁺ Significance is present between controlled diabetics and control group.

BMI: Body mass index. HbA1c: Glycosylated hemoglobin. F P glucose: Fasting plasma glucose.

GFR: Glomerular filtration rate. HDL: high density lipoprotein.

Fasting plasma glucose levels were significantly higher in the uncontrolled diabetic group (127.3 ± 20.2) than in the controlled diabetic group (92.2 ± 12.82) and healthy control group (82.3 ± 7.8) {p<0.001}, and also there was a significant increase in F P glucose in the controlled diabetic group as compared to healthy control group {p<0.001}.

Hemoglobin A1c (HbA1c) was significantly higher in the uncontrolled diabetic group (11.0 ± 2.1) than in the controlled diabetic group (6.2 ± 0.7) and healthy control group (5.4 ± 0.5) {p<0.001}, and also there was a significant increase in HbA1c in the controlled diabetic group as compared to healthy control group {p<0.001}.

Serum creatinine levels were significantly higher in both the uncontrolled diabetic group (0.95 ± 0.19) and controlled diabetic group (0.9 ± 0.18) than in the healthy control group (0.55 ± 0.12) {p<0.001},

there was no significant difference in Serum creatinine between the uncontrolled and controlled diabetic groups.

GFR levels were significantly lower in both the uncontrolled diabetic group (95.5±17.7) and controlled diabetic group (103.1±14.6) than in the healthy control group (126.4±14.6) {p<0.001}, there was no significant difference in GFR between the uncontrolled and controlled diabetic groups.

Albumin excretion in urine was significantly higher in the uncontrolled diabetic group (243±140.5) than in the controlled diabetic group (188.4±114) and healthy control group (6.7±3.1) {p<0.001}, and also there was a significant increase in urinary Albumin excretion in the controlled diabetic group as compared to healthy control group {p<0.001}.

Triglyceride and cholesterol levels were significantly higher in both the uncontrolled diabetic

group (157.2 ± 49.4 and 205 ± 47.1 , respectively) and controlled diabetic group (160.2 ± 43.7 and 194.5 ± 42.3 , respectively) than in the healthy control group (119.2 ± 23.3 and 160.2 ± 23.3 , respectively) $\{p < 0.001\}$, there were no significant difference in triglyceride or cholesterol levels between the uncontrolled and controlled diabetic groups.

HDL levels were significantly lower in both the uncontrolled diabetic group (42.7 ± 8.1) and controlled diabetic group (45.9 ± 7.0) than healthy control group

(52.5 ± 9.7) $\{p < 0.001\}$, there was no significant difference in HDL between the uncontrolled diabetic and controlled diabetic groups.

Serum fetuin-A levels were significantly lower in the uncontrolled diabetic group (252.4 ± 55.6) and the controlled diabetic group (314 ± 66.8) than in the healthy control group (478.6 ± 74.4) $\{p < 0.001\}$, and also there was a significant reduction in serum fetuin-A in uncontrolled diabetic group as compared to controlled diabetic group ($p < 0.001$).

Table 2: Correlation between Serum fetuin and other Parameters of the study.

Parameter	Serum fetuin	
	r	P
Age	-0.09	> 0.05
Body mass index	0.001	> 0.05
Systolic blood pressure	-0.19	>0.05
Diastolic blood pressure	-0.03	>0.05
Duration of diabetes	0.02	>0.05
Glycoselated HbA1c	-0.55	<0.001*
Fasting plasma glucose	-0.52	<0.001*
Serum creatinine	-0.61	<0.001*
Serum albumin	0.06	>0.05
Triglycerides	-0.15	>0.05
Total cholesterol	-0.21	>0.05
high density lipoprotein	0.2	>0.05
Glomerular filtration rate	0.53	<0.001*
Albumin excretion in urine	-0.56	<0.001*

* Correlation is highly significant.

The overall mean serum level of fetuin-A was 348.36 ± 116.1 mg/L with a range of 170 to 620 mg/L. Correlation study revealed that each of HbA1c, FP glucose, serum creatinine and Albumin excretion were significantly and inversely associated with serum fetuin-A levels ($r = -0.55, -0.52, -0.61$, and -0.56 respectively; $P < 0.001$ for each), whereas; GFR was significantly positively associated with serum fetuin-A levels ($r = 0.53, P < 0.001$). No other clinical or metabolic variable (as BMI, blood pressure, total cholesterol, HDL and triglyceride) was significantly correlated in these groups of diabetic patients with serum fetuin-A ($P > 0.05$ in all, see table 2). The overall mean serum level of fetuin-A in male individuals was 347.5 ± 126.5 mg/L, with no significant difference from that of female individuals (346.5 ± 107.6 mg/L, $p = 0.97$).

4. Discussion

The gene encoding fetuin-A is located on chromosome 3q27, the chromosomal region that was previously mapped as a type 2 diabetes and metabolic syndrome susceptibility locus (12). The aforementioned findings and the animal studies showing that fetuin-A induces insulin resistance (13-

16) resulted in the view that fetuin-A is an interesting candidate involved in the pathophysiology of type 2 diabetes. Genetic analyses revealing that single nucleotide polymorphisms in the fetuin-A gene were associated with type 2 diabetes in cross-sectional studies (17) further corroborated this hypothesis. However, the role of fetuin-A in the natural history of type 2 diabetes still remained obscure. Fetuin-A, besides the placenta, is exclusively secreted from the liver (18). Expression of fetuin-A and plasma levels of the protein were found to be increased when there is fat accumulation in the liver (19,20) and circulating fetuin-A is increased in the metabolic syndrome (21), the condition that strongly associates with fatty liver (22). Moreover, fetuin-A complexes with calcium and phosphorus in the circulation and prevents the precipitation of these minerals in serum [23,24]. Fetuin-A is regarded as marker for vascular inflammation and as one of the most potent negative regulators of vascular ossification - calcification [25,26]. In animals lacking the fetuin-A gene, the aorta was found to be spared of calcification and fibrosis, whereas peripheral vessels in the skin and kidney showed evidence of extensive calcification,

and the small artery involvement preceded the impairment of renal function [24,27].

In this study, we evaluated the associations of parameters of microvascular disease in patients with T2DM and early diabetic nephropathy as the degree of albumin excretion and renal function (GFR and serum creatinine) with fetuin-A.

This study demonstrates that lower fetuin-A levels seem to be associated with microvascular complications in patients with early diabetic nephropathy disease in type 2 diabetes as evidenced by the significant inverse association between fetuin-A concentrations and the degree of 24 h urinary albumin excretion and also, the significant positive association between fetuin-A concentrations and GFR.

Furthermore, we could show that there is a link between fetuin-A serum levels and state of diabetes control which was determined by inverse association between fetuin-A concentrations and HbA1c.

In addition, fetuin-A levels do not correlate with some clinical and metabolic parameters as BMI, blood pressure, total cholesterol, HDL and triglyceride in our type 2 diabetic patients with early diabetic nephropathy with or without hyperglycemia.

The data presented herein allows to speculate, that fetuin-A could play a role in the development of early microvascular disease (especially nephropathy) in type 2 diabetes, yet possible mechanisms remain unclear. In line with this hypothesis, Eraso et al. showed that circulating fetuin-A was lower in 38 subjects with type 2 diabetes and an ankle/brachial index (ABI)<0.9, compared with 700 diabetes controls [28]. Also Roos et al assessed ABI as a parameter of microvascular disease and demonstrated that type 2 diabetic patients with an ABI<0.9 had lower fetuin-A levels than patients with an ABI 0.9-1.3 or >1.3 and that fetuin-A was significantly associated with ABI. Moreover, Roos et al. found that lower fetuin-A levels seem to be associated with prevalent macrovascular disease (as coronary artery disease, stroke and peripheral artery disease) in type 2 diabetes. But in contrast to our results, they showed also that fetuin-A serum levels are not associated with microvascular complications (24 h urinary albumin excretion) in patients with early diabetic nephropathy. In addition, they agree with us to some extent in that fetuin-A levels do not correlate with metabolic parameters in their type 2 diabetes patients with prevalent late complications [29].

Again, a recently published study in patients without diabetes and renal impairment demonstrated decreased fetuin-A serum levels in patients suffering from advanced three-vessel disease compared with those without stenosis [30]. These finding go in line

with our assumption of reduced fetuin-A serum levels in patients with diabetic nephropathy.

Reviewing the existing data as well as the results obtained in this study, it may be assumed that fetuin-A levels are lower in type 2 diabetes patients with early diabetic nephropathy especially those with uncontrolled diabetes.

Our results are in contrast to findings in several cross-sectional studies which showed an association of high fetuin-A levels with impaired glucose tolerance, metabolic syndrome and an atherogenic lipid profile (high low-density lipoprotein, high triglyceride concentrations and low HDL concentrations) [31,32] and the positive association of Plasma fetuin-A levels with the risk of type 2 diabetes [33].

We recognize the limitations of the present study. Our approach is limited by the small samples size. Therefore, especially the data for associations with microvascular disease and renal function in type 2 diabetes will have to be reproduced in larger groups.

5. Conclusions

In this study, low plasma fetuin-A levels predict microvascular complications in type 2 diabetes with early diabetic nephropathy and also there are associations of fetuin-A with hyperglycemia in these patients.

Corresponding author

Ayman Ramadan Abd El-Hai
Internal Medicine, Department, Faculty of Medicine,
Zagazig University, Zagazig, Egypt
aymedman@yahoo.co.uk

6. References:

1. St Clair L a-and Ballantyne CM: Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. *Am J Cardiol* 2007, 99:80B-88B.
2. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med* 2008, 358:2107-2116.
3. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. *Arch Intern Med* 2006, 166:1368-1373.
4. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG: Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. *J Am Coll Cardiol* 2010, 55:2080-2091.
5. Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilie S, Eyiletin T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A and Yenicesu M. Endothelial dysfunction and fetuin-A levels before and after kidney transplantation. *Transplantation* 2007; 83: 392-397.
6. Brandenburg VC, Parker BD, and Ix JH. Important Differences in Measurement of Fetuin-A. *Annals of Internal Medicine* 2010; 153 (6): 419-420.

7. Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N and Matsumoto K: Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. *Clin Exp Nephrol* 2007; 11: 336-337.
8. Cottone S, Lorito MC, Riccobene R, Nardi E, Mule G, Buscemi S, Geraci C, Guarneri M, Arseno R and Cerasola G: Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. *J Nephrol* 2008; 21:175-179.
9. Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyiletten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B: Serum fetuin-A concentration and endothelial dysfunction in chronic kidney disease. *Nephron Clin Pract* 2008;108(3):233-240.
10. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* 2005, 28:164-76, Review.
11. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Chronic Kidney disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem* 2007, 53:766-72.
12. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genome wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. *Am J Hum Genet* 2000; 67:1470-1480.
13. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. *Cell* 1989; 58:631-640.
14. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, Grunberger G: Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. *Mol Cell Endocrinol* 2000; 164:87-98.
15. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Haring HU, Nawratil P, Haasemann M, Jahnen-Dechent W, Muller-Esterl W: The nucleotide and partial amino acid sequences of rat fetuin: identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. *Eur J Biochem* 1992; 204:523-529.
16. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, and Grunberger G: Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. *Diabetes* 2002; 51:2450-2458.
17. Siddiq A, Lepretre F, Hercberg S, Froguel P, and Gibson F: A synonymous coding polymorphism in the alpha2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. *Diabetes* 2005; 54(8):2477-2481.
18. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W: Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. *Biochem J* 2003; 376:135-145.
19. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* 2006; 29(4):853- 857.
20. Lin X, Braymer HD, Bray GA, York DA: Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. *Life Sci* 1998; 63:145-153.
21. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. *Circulation* 2006; 113:1760-1767.
22. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008; 28:27-38.
23. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin A. Formation of colloidal calciprotein particles. *J Biol Chem* 2003, 278:13333-13341.
24. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, and Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* 2003, 112:357-366.
25. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification -calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriopathy: the emerging role of sodium thiosulfate. *Cardiovascular Diabetology* 2005, 4(1):4.
26. Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation end product N-Carboxymethyllysine (CML). *Cardiovascular Diabetology* 2009, 8:45.
27. Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. *J Am Soc Nephrol* 2005, 16:3357-3364.
28. Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER, Reilly MP: Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes. *Diabetes Care* 2010, 33:408-410.
29. Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, Baumann M, Nawroth PP, Bierhaus A, Humpert PM: Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. *Cardiovascular Diabetology* 2010, 9:48.
30. Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, and Nishizawa Y: Fetuin-A is associated with calcified coronary artery disease. *Coron Artery Dis* 2010, 21:281-5.
31. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A: Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. *Circulation* 2008, 118:2555-2562.
32. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul study. *Circulation* 2006, 113:1760-1767.
33. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. *Diabetes* 2008, 57:2762-2767.

4/5/2011